Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4714042 | 1.00 | ADRB1 (0.34) | ADRB1IRAK4TRPV3BACE1KCNH2 | |
| SCHEMBL20436445 | 1.00 | ADRB1 (0.34) | ADRB1IRAK4TRPV3BACE1KCNH2 | |
| SCHEMBL20416725 | 0.88 | ADORA2A (0.35) | ADRB1IRAK4BACE1KCNH2 | |
| SCHEMBL20442096 | 0.87 | IRAK4 (0.33) | ADRB1IRAK4TRPV3BACE1KCNH2 | |
| SCHEMBL16402618 | 0.85 | ADRB1 (0.38) | ADRB1IRAK4BACE1 | |
| SCHEMBL5518710 | 0.85 | IRAK4 (0.33) | IRAK4BACE1KCNH2 | |
| SCHEMBL20417086 | 0.85 | IRAK4 (0.34) | IRAK4BACE1KCNH2 | |
| SCHEMBL24915370 | 0.84 | IRAK4 (0.32) | IRAK4BACE1KCNH2 | |
| SCHEMBL20436441 | 0.84 | IRAK4 (0.35) | IRAK4BACE1KCNH2 | |
| SCHEMBL20416709 | 0.84 | IRAK4 (0.32) | IRAK4BACE1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144808-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11072597-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. | 2021-07-27 | — | — | US | disclosed |
| US-20210101880-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2021-04-08 | — | — | US | disclosed |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | MERCK & CO., INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | MERCK & CO., INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144808-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | ADRB1 690/4885IRAK4 759/4885TRPV3 3793/4885 |
| US-11072597-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ADORA2A, ADORA2B, ADORA1 | ADRB1 690/4885IRAK4 759/4885TRPV3 3793/4885 |
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | PER2, CNR2, OPRD1 | ADRB1 192/4885IRAK4 1806/4885TRPV3 120/4885 |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | ADRB1 690/4885IRAK4 759/4885TRPV3 3793/4885 |
| US-20210101880-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | ADRB1 690/4885IRAK4 759/4885TRPV3 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.